A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran
Crossref DOI link: https://doi.org/10.1007/s40119-016-0071-5
Published Online: 2016-10-05
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
O’Dea, Daniel
Whetteckey, Jacqueline
Ting, Naitee
Funding for this research was provided by:
Boehringer Ingelheim Pharmaceuticals, Inc
